Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.35 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP3A43 | Q9HB55 | 1/20 | 0.35 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1553635 | 0.83 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 | |
| SCHEMBL2625489 | 0.83 | CYP11B1 (0.40) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 | |
| SCHEMBL31214086 | 0.76 | CYP11B1 (0.39) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 | |
| SCHEMBL22368312 | 0.75 | CYP3A4 (0.40) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 | |
| SCHEMBL2371326 | 0.72 | AKR1C3 (0.38) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 | |
| SCHEMBL2371309 | 0.71 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 | |
| Lithium Ion SCHEMBL2370296 | 0.71 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 | |
| Potassium Ion SCHEMBL2370572 | 0.71 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 | |
| SCHEMBL30577163 | 0.68 | SMN1; SMN2 (0.44) | — | |
| SCHEMBL14562495 | 0.68 | HCAR2 (0.34) | CYP3A4CYP2C9CYP2B6CYP3A5CYP3A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050272747-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER INC | 2005-12-08 | — | — | US | claimed |
| EP-0871625-B1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RES ANDDEVELOPMENT COMP (IE) | 2003-12-17 | — | — | EP | claimed |
| US-20030181720-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | BUTTERS MICHAEL (GB) | 2003-09-25 | — | — | US | claimed |
| EP-0871625-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-10-21 | — | — | EP | claimed |
| WO-1997006160-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-02-20 | — | — | WO | claimed |
| CN-113354625-B | Synthesis process of voriconazole | 安徽普利药业有限公司 | 2023-09-26 | — | — | CN | disclosed |
| CN-113354625-A | Synthesis process of voriconazole | 安徽普利药业有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-7193083-B2 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER, INC. (US) | 2007-03-20 | — | — | US | disclosed |
| US-20050272747-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER INC | 2005-12-08 | — | — | US | disclosed |
| US-6946555-B2 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | PFIZER INC (US) | 2005-09-20 | — | — | US | disclosed |
| EP-0871625-B1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RES ANDDEVELOPMENT COMP (IE) | 2003-12-17 | — | — | EP | disclosed |
| US-20030181720-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | BUTTERS MICHAEL (GB) | 2003-09-25 | — | — | US | disclosed |
| US-6586594-B1 | Reacting 1-(2,4-difluorophenyl)-2-(1H-1,2,4-triazol-1-yl) ethanone and 6-(1-bromoethyl)-4-chloro-5-fluoropyrimidine in the presence of zinc, iodine, lewis acids, aprotic solvents and optionally lead to form sterospecific fungicides | PFIZER, INC. | 2003-07-01 | — | — | US | disclosed |
| EP-0871625-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | Pfizer Research and Development Company, N.V./S.A. (IE) | 1998-10-21 | — | — | EP | disclosed |
| WO-1997006160-A1 | PREPARATION OF TRIAZOLES BY ORGANOMETALLIC ADDITION TO KETONES AND INTERMEDIATES THEREFOR | PFIZER RESEARCH AND DEVELOPMENT COMPANY, N.V./S.A. (IE) | 1997-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181720-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | IKZF2, SLC39A11, IKZF3 | CYP3A4 169/4885CYP2C9 624/4885CYP2B6 164/4885 |
| US-20050272747-A1 | Preparation of triazoles by organometallic addition to ketones and intermediates therefor | SLC39A11, IKZF2, IKZF3 | CYP3A4 149/4885CYP2C9 476/4885CYP2B6 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.